IL17A and colitis: Consistent with the capacity of BFT to diminish colon barrier function, mice colonized (by oral gavage) with ETBF develop acute IL-17-dominant colitis followed by protracted (~1 year) ongoing colonization, chronic colon inflammation, and persistent excess mucosal IL-1721,22.